Although numerous PI3K/AKT/mTOR pathway inhibitors have been extensively studied, their potential adverse effects, such as severe hepatotoxicity and pneumonitis, have largely restricted the clinical application of these inhibitors (Zhang et al., 2019). Here, AKT1 is linked to pneumonitis.